D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for treating newly diagnosed HIV-1 infection before baseline laboratory results are available, according to results from the DIAMOND phase-3 study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 21, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Truvada should remain first choice for HIV prevention, experts say
(Harvard Pilgrim Health Care Institute) In October 2019, the FDA approved a second medication for use as HIV preexposure prophylaxis, also known as PrEP, sparking controversy about which drug should be prescribed. Gilead Sciences, which manufactures both approved drugs, has argued that the new drug is safer and more effective than the old drug. But these claims are overstated, say a team of clinical and public health experts. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 13, 2020 Category: Infectious Diseases Source Type: news

Four-Drug Combination Effective Long-Term for HIV Suppression Four-Drug Combination Effective Long-Term for HIV Suppression
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for long-term viral suppression in previously untreated patients with HIV-1 infection, according to 96-week results from the AMBER trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 3, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Facebook Asked to Remove'Factually Inaccurate' Ads About PrEP
THURSDAY, Dec. 12, 2019 -- Facebook should remove " factually inaccurate " ads that " suggest negative health effects " of the HIV-prevention medication Truvada, more than 50 LGBTQ, HIV, and public health groups say in an open letter to the company. The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2019 Category: Pharmaceuticals Source Type: news

Activists and LGBTQ Groups Say These Facebook Ads Spread Dangerous Misinformation About HIV Drugs
Advocacy groups are urging Facebook to remove advertisements that they say unfairly infer that the HIV/AIDS prevention Truvada PrEP (pre-exposure prophylaxis) is dangerous, an allegation they say could endanger the people who are most at risk of contracting the disease. More than 50 HIV/AIDs, LGBTQ and public health advocacy groups released a letter on Monday asking Facebook and Instagram to remove the ads from their platforms. The ads referred specifically to “Truvada PrEP” (the brand name for one of the medications, dtenofovir disoproxil fumarate, used as PrEP) and in some cases more generically to “PrE...
Source: TIME: Health - December 11, 2019 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized health LGBTQ onetime Source Type: news

200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs
A new government program will provide donated drugs through major drugstore chains. (Source: NYT Health)
Source: NYT Health - December 3, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome PrEP (Pre-exposure prophylaxis for H.I.V.) Truvada (Drug) Gilead Sciences Inc Health and Human Services Department Azar, Alex M II Drugs (Pharmaceuticals) Tests (Medical) Health Insurance and Managed Car Source Type: news

200,000 People Without Insurance May Apply for Free H.I.V.-Prevention Drugs
A new government program will provide donated drugs through major drugstore chains. (Source: NYT Health)
Source: NYT Health - December 3, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome PrEP (Pre-exposure prophylaxis for H.I.V.) Truvada (Drug) Gilead Sciences Inc Health and Human Services Department Azar, Alex M II Drugs (Pharmaceuticals) Tests (Medical) Health Insurance and Managed Car Source Type: news

Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says
In an unexpected lawsuit, federal officials claim that Gilead Sciences willfully disregarded government patents on medicines necessary to end the AIDS epidemic. (Source: NYT Health)
Source: NYT Health - November 8, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. and Apoorva Mandavilli Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Inventions and Patents Drugs (Pharmaceuticals) Royalties Health and Human Services Department National Institutes of Health Azar, Alex M II Cummings, Elijah E Stabenow, Debbie Source Type: news

Trump Administration Sues Gilead, Maker of H.I.V.-Prevention Drugs
The lawsuit accused the pharmaceutical company of profiting billions of dollars off taxpayer research without paying royalties. (Source: NYT Health)
Source: NYT Health - November 7, 2019 Category: Consumer Health News Authors: Daniel Victor Tags: Gilead Sciences Inc Truvada (Drug) Health and Human Services Department Inventions and Patents Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Source Type: news

California Makes H.I.V.-Prevention Drugs Available Without a Prescription
The state is the first in the nation to allow pharmacists to dispense PrEP and PEP, drugs that can prevent new H.I.V. infections. (Source: NYT Health)
Source: NYT Health - October 9, 2019 Category: Consumer Health News Authors: Karen Zraick and Sandra E. Garcia Tags: Drugs (Pharmaceuticals) Truvada (Drug) Acquired Immune Deficiency Syndrome Drug Resistance (Microbial) Drugstores Equality California Newsom, Gavin Source Type: news

F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Everyone
Citing a lack of evidence, the agency will require Gilead to conduct additional trials in individuals ‘who have receptive vaginal sex.’ (Source: NYT Health)
Source: NYT Health - October 8, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news

F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Cisgender Women
Citing a lack of evidence, the agency will require Gilead to conduct additional trials. (Source: NYT Health)
Source: NYT Health - October 8, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news

F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Women
Citing a lack of evidence, the agency will require Gilead to conduct further trials in women. (Source: NYT Health)
Source: NYT Health - October 4, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news

FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) indication for Descovy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 4, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs Descovy, Second Drug for HIV PrEP FDA OKs Descovy, Second Drug for HIV PrEP
The combo of emtricitabine and tenofovir alafenamide is indicated to reduce the risk for HIV-1 infection from sex (excluding receptive vaginal sex) in at-risk adults and teens weighing at least 35 kg.FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 3, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. (Source: World Pharma News)
Source: World Pharma News - October 3, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Gilead to challenge US patents on HIV drug Truvada
Move comes amid increasing scrutiny of drugmaker over pricing practices (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 21, 2019 Category: Pharmaceuticals Source Type: news

Gilead did not seek US exclusivity on PrEP with Truvada
Drugmaker could be liable for billions in royalties to US government (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 18, 2019 Category: Pharmaceuticals Source Type: news

Would You Want a Computer to Judge Your Risk of H.I.V. Infection?
A new software algorithm decides which patients are most likely to become infected with the virus. But this is not like other risk calculators, some experts say. (Source: NYT Health)
Source: NYT Health - July 30, 2019 Category: Consumer Health News Authors: Gina Kolata Tags: Tests (Medical) Truvada (Drug) Acquired Immune Deficiency Syndrome Electronic Health Records Computers and the Internet Homosexuality and Bisexuality Sexually Transmitted Diseases Harvard University Kaiser Permanente United States Source Type: news

Most High-Risk Men Don ’t Take PrEP to Prevent H.I.V.
In a survey, only about one in three American men who were at high risk for H.I.V. infection took Truvada to prevent transmission. (Source: NYT Health)
Source: NYT Health - July 25, 2019 Category: Consumer Health News Authors: Toby Bilanow Tags: Truvada (Drug) Acquired Immune Deficiency Syndrome Sexually Transmitted Diseases Blacks Condoms Hispanic-Americans Source Type: news

Someday, an Arm Implant May Prevent H.I.V. Infection for a Year
In preliminary tests, a matchstick-size rod containing a new drug offered promise as a shield against the virus. But a large clinical trial must still be done. (Source: NYT Health)
Source: NYT Health - July 23, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Inventions and Patents Implants Merck & Company Inc National Institute for Allergy and Infectious Disease (NIAID) Fauci, Anthony S Africa Source Type: news

PrEP use high but wanes after three months among young African women
(NIH/National Institute of Allergy and Infectious Diseases) In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among young African women and adolescent girls, 95% initiated PrEP, and most used PrEP for the first three months. However, PrEP use fell in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored strategies may be needed to engage young African women in consistent PrEP use. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 23, 2019 Category: Infectious Diseases Source Type: news

Lower than expected risk of bone density decline with Truvada PrEP
(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use -- very high adherence -- had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2019 Category: International Medicine & Public Health Source Type: news

How Australia Could Almost Eradicate H.I.V. Transmissions
The most recent advance in Australia ’s decades-long fight against the virus is the rapid adoption of a preventive drug regimen known as PrEP. (Source: NYT Health)
Source: NYT Health - July 11, 2019 Category: Consumer Health News Authors: Livia Albeck-Ripka Tags: Truvada (Drug) Acquired Immune Deficiency Syndrome Health Insurance and Managed Care Homosexuality and Bisexuality Australia United States Source Type: news

Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2019 Category: Drugs & Pharmacology Source Type: news

FDA In Brief: FDA continues to encourage ongoing education about the benefits and risks associated with PrEP, including additional steps to help reduce the risk of getting HIV
Because patients and doctors understand the risks of using Truvada for PrEP, and educational materials are available from CDC, FDA eliminated the REMS for Truvada and its generics. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 2, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

UCLA Health to launch fellowship focused on LGBTQ care
To help ensure that future primary care doctors are able to address the physical and mental health care needs of people who are LGBTQ, UCLA Health has created an immersive, one-year fellowship focused on LGBTQ-centered care.TheUCLA LGBTQ Fellowship, which starts on July 1, was conceived about a year ago by faculty in the internal medicine department at theDavid Geffen School of Medicine at UCLA to address LGBTQ-specific topics, which often are not adequately addressed in medical school and residency training.The training will help doctors provide the best counsel for disease prevention and screening, sexual and behavioral ...
Source: UCLA Newsroom: Health Sciences - June 22, 2019 Category: Universities & Medical Training Source Type: news

Expert Panel Backs PrEP for People at High HIV Risk
Best known as the two-drug combo pill Truvada, PrEP prevents HIV from establishing a permanent infection in people exposed through sex or injection drug use, the CDC says. (Source: WebMD Health)
Source: WebMD Health - June 11, 2019 Category: Consumer Health News Source Type: news

For the First Time, an Expert Panel Is Recommending a Drug to Prevent High-Risk Groups From Getting HIV
Over the past few decades, doctors and researchers have made admirable progress in controlling the spread of HIV, mainly by using anti-HIV drugs in powerful combinations that can make it harder for the virus to infect cells and pump out more copies of itself. But as any infectious-disease expert knows, preventing new infections is equally as important as treating existing cases to contain an epidemic. And in the U.S. each year, nearly 40,000 people are still newly diagnosed with HIV. With its latest recommendation, published in JAMA, the U.S. Preventive Services Task Force (USPSTF) issued its strongest strategy yet for pre...
Source: TIME: Health - June 11, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized HIV hiv prevention Infectious Disease Source Type: news

U.S. Expert Panel Supports HIV-Prevention Pill Truvada, for People at High Risk
TUESDAY, June 11, 2019 -- A daily pill that can block transmission of HIV should be prescribed to people at high risk of infection with the AIDS-causing virus, according to a highly influential panel of experts. The treatment -- called pre-exposure... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2019 Category: General Medicine Source Type: news

Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment Bictegravir-Based Regimen Noninferior to Dolutegravir-Based Regimens for HIV Treatment
A single-tablet regimen of bictegravir, emtricitabine and tenofovir alafenamide is noninferior to regimens of dolutegravir coformulated with emtricitabine and tenofovir alafenamide or with abacavir and lamivudine for the initial treatment of HIV-1 infection, according to results from two randomized phase 3 trials.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 7, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Health activists fighting to lower cost of a revolutionary HIV drug
The organization PrEP4All is facing off with a major pharmaceutical company over the growing price of Truvada, a revolutionary HIV drug. A 30-day supply of Truvada costs around $1,700. No cheaper version of the same drug is available in the United States. Health advocate Emily Sanderson joins CBSN to disucss. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 5, 2019 Category: Consumer Health News Source Type: news

Gilead to Donate Truvada to CDC to Help With HIV PrEP in US Gilead to Donate Truvada to CDC to Help With HIV PrEP in US
While the Trump administration praised the donation, activists maintained their call for a reduction in the cost of the antiviral treatment, now pegged at more than $20,000 a year.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 14, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Gilead to donate HIV meds to 200K people
The company is planning to donate Truvada to these patients for up to 11 years in a move meant to end the HIV epidemic. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 13, 2019 Category: Pharmaceuticals Source Type: news

Gilead, HHS chief announce donation of HIV prevention drug Truvada
Health and Human Services Secretary Alex M. Azar announced a deal this week for drugmaker Gilead Sciences to donate billions of dollars in HIV prevention drugs over the course of the next decade. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 10, 2019 Category: Consumer Health News Source Type: news

Global Health: Gilead Will Donate Truvada to U.S. for H.I.V. Prevention
The manufacturer will provide enough of the drug to supply 200,000 patients annually for more than a decade. Critics said it would not be enough to end the AIDS epidemic and questioned the company ’ s motives. (Source: NYT Health)
Source: NYT Health - May 10, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Generic Brands and Products State of the Union Message (US) Gilead Sciences Inc United States Drugs (Pharmaceuticals) Source Type: news

Generic Version of Truvada Available in U.S. by Sept. 2020
THURSDAY, May 9, 2019 -- A generic version of the HIV preexposure prophylaxis (PrEP) drug Truvada will be available in the United States by September 2020, a year earlier than expected, according to Gilead Sciences. " Gilead reached an agreement with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 9, 2019 Category: Pharmaceuticals Source Type: news

'The people that most need this drug can't afford it': HIV advocates target Gilead meeting, but company says they're wrong
In shout-down with Gilead management, groups say company's patent for Truvada — the only drug approved for preventing new HIV infections — should be stripped. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 8, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

'The people that most need this drug can't afford it': HIV advocates target Gilead meeting, but company says they're wrong
In shout-down with Gilead management, groups say company's patent for Truvada — the only drug approved for preventing new HIV infections — should be stripped. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 8, 2019 Category: American Health Authors: Ron Leuty Source Type: news

Trump ’ s Proposed Budget Undermines His H.I.V. Plan, Experts Say
Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle. (Source: NYT Health)
Source: NYT Health - March 13, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Federal Budget (US) Truvada (Drug) United States Politics and Government Medicaid Epidemics Medicare Trump, Donald J Drugs (Pharmaceuticals) Budgets and Budgeting Prices (Fares, Fees and Rates) Source Type: news

Global Health: Bit by Bit, Scientists Gain Ground on AIDS
The “ London patient, ” apparently cured of H.I.V. infection, has gotten all the attention. But other recently revealed advances are more likely to affect the immediate course of the AIDS epidemic. (Source: NYT Health)
Source: NYT Health - March 9, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Tests (Medical) Drugs (Pharmaceuticals) Third World and Developing Countries Truvada (Drug) Epidemics Gilead Sciences Inc Africa Source Type: news

Global Health: Scientists Are Gaining Ground Against AIDS
The “ London patient, ” apparently cured of H.I.V. infection, has gotten all the attention. But other recently revealed advances are more likely to affect the immediate course of the AIDS epidemic. (Source: NYT Health)
Source: NYT Health - March 9, 2019 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Acquired Immune Deficiency Syndrome Tests (Medical) Drugs (Pharmaceuticals) Third World and Developing Countries Truvada (Drug) Epidemics Gilead Sciences Inc Africa Source Type: news

' Grappling' With the Value of Descovy for HIV PrEP'Grappling' With the Value of Descovy for HIV PrEP
A new study shows that Descovy for pre-exposure prophylaxis (PrEP) is noninferior to Truvada. But as the field moves toward treating those most at risk, some question how much it matters.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 7, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Truvada Meets Its Match for PrEP
(MedPage Today) -- Placebo-less DISCOVER trial marks " dawn of a new age of prevention studies " (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - March 7, 2019 Category: Infectious Diseases Source Type: news

Dr. Mags Portman, HIV Prevention Pioneer, Dies from Mesothelioma at 44
Dr. Mags Portman, a British trailblazer in the fight to prevent and control HIV, died Wednesday after a two-year battle with mesothelioma. She was 44. Portman was lauded for triggering a significant reduction in HIV diagnoses throughout the United Kingdom by her work as a researcher, clinician and outspoken advocate. She earned international acclaim for her work as an HIV consultant at London’s Mortimer Market Centre, a progressive sexual health clinic that made pre-exposure prophylaxis (PrEP) a reality in the U.K. Portman played a key role in the 2014 study at The Royal London Hospital that proved the efficacy of t...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir   Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 7, 2019 Category: Drugs & Pharmacology Source Type: news

Facing Legal Action, Insurer Now Will Cover People Taking Truvada, an H.I.V.-Prevention Drug
Regulators had accused Mutual of Omaha of denying policies to applicants, mostly gay men, who took medication to protect against the infection. (Source: NYT Health)
Source: NYT Health - January 11, 2019 Category: Consumer Health News Authors: GINA KOLATA Tags: Discrimination Truvada (Drug) Health Insurance and Managed Care Disability Insurance Homosexuality and Bisexuality Acquired Immune Deficiency Syndrome Infections Consumer Protection Suits and Litigation (Civil) Centers for Disease Contro Source Type: news

Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients Four-drug Combo Pill for HIV an Option in Chronic Dialysis Patients
A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, approved in the U.S. and elsewhere for HIV-1-infected patients with mild-to-moderate chronic kidney disease, may also work well in those with end-stage renal disease on chronic hemodialysis, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Task Force Calls for Offering PrEP to All at High Risk for H.I.V.
The recommendation would include all men and women whose sexual behavior, sex partners or drug use place them at high risk of contracting the virus that causes AIDS. (Source: NYT Health)
Source: NYT Health - November 20, 2018 Category: Consumer Health News Authors: RONI CARYN RABIN Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Condoms Preventive Medicine Drugs (Pharmaceuticals) Sex Minorities Source Type: news

This Is the Best Way to Prevent HIV, Expert Group Says
While there is no vaccine yet to protect against HIV, doctors have an effective drug to prevent HIV infection. After impressive studies overseas and in the U.S., the Food and Drug Administration approved Truvada, a combination of anti-HIV drugs, in 2012 as the first medication that can prevent healthy people from getting infected with HIV by up to 90%. Now, for the first time, a group of independent experts convened by the government, the U.S. Preventive Services Task Force (USPSTF), is recommending that people at high risk of acquiring HIV infection be prescribed the drug, also known as pre-exposure prophylaxis (PrEP). Th...
Source: TIME: Health - November 20, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized hiv-aids Source Type: news